AUS
NZ
UK
CA
USA
IND
ResMed CDI has been on a remarkable upward trajectory in 2024, with its share price surging 42.6% since the start of the year. Investors are taking a keen interest in RMD shares (ASX:RMD), and several factors are contributing to this impressive performance.
ResMed CDI: Company
Founded in Australia in 1989 by Peter Farrell, ResMed has grown into a global leader in medical equipment. Although the company is now headquartered in San Diego, California, its roots are firmly planted in Australia. ResMed specializes in cloud-connectable continuous positive airway pressure (CPAP) machines, which are used to treat obstructive sleep apnea (OSA). The company’s shares are listed on both the New York Stock Exchange (NYSE) and the ASX.
ResMed operates worldwide with a workforce exceeding 10,000 employees and a presence in over 140 countries. The company is divided into two primary business units: Sleep and Respiratory Care, and Software as a Service (SaaS). The Sleep and Respiratory Care unit focuses on providing CPAP machines and other equipment for managing sleep apnea and respiratory conditions. The SaaS unit offers software solutions that assist with durable or home medical equipment (DME/HME), enhancing out-of-hospital care.
ResMed leverages its extensive digital health network, powered by its cloud-connected devices, to gather valuable data and insights. This capability allows the company to improve patient outcomes and reduce overall healthcare costs.
The Appeal of Healthcare Stocks
Healthcare stocks, including ResMed, are increasingly appealing for several reasons:
- Stable Revenue:
Healthcare is considered an essential service, which means spending in this sector is often more stable compared to other industries. Even during economic downturns, people prioritize healthcare, making revenue streams for healthcare companies relatively consistent. Historically, healthcare has shown resilience, even outperforming other sectors during economic crises.
- Growth Potential:
The healthcare sector, particularly in the United States, is experiencing significant growth. The US, which represents over 40% of global healthcare spending, is projected to see annual profit increases of 7% from 2022 to 2027, reaching US$819 billion. Specific sub-sectors, such as those providing IT and data solutions, are expected to grow at more than 15% per year from 2024 to 2030, underscoring the sector's robust expansion.
- Ethical Investing:
A recent survey indicates a rising trend towards sustainable and ethical investments. With increasing interest in socially responsible investing, healthcare companies that provide essential public services, like ResMed, are well-positioned to benefit from this shift in investor priorities.
Evaluating ResMed CDI's Valuation
As a growth-oriented company, assessing the value of ResMed CDI shares involves looking at various metrics. Currently, ResMed's price-to-sales ratio stands at 5.12x. This is below its 5-year average of 6.13x, suggesting that the shares are trading at a lower valuation relative to historical levels. However, it's important to consider that this is just one valuation method, and making investment decisions should involve a comprehensive analysis of multiple factors.
ResMed CDI (ASX:RMD) has demonstrated impressive growth in 2024, driven by its strong performance in the healthcare sector. With its innovative medical solutions and strategic global presence, ResMed continues to capture investor interest. The stability of healthcare spending, coupled with significant growth potential and increasing ethical investment trends, further enhances the appeal of ResMed shares. As always, evaluating a company's value involves looking at various metrics and understanding broader market trends.
